Roche Lung-Cancer Drug Candidate Beats Existing Therapies in Late-Stage Trial
Roche's KRAS G12C inhibitor, divarasib, outperformed rival therapies in a head-to-head Phase 3 trial for lung cancer.
📍 The outcome
Roche's KRAS G12C inhibitor, divarasib, beat rivals from Amgen and BMS in a head-to-head Phase 3 study for NSCLC. The drug candidate succeeded in the late-stage trial and set a new standard for KRAS-driven lung cancer.
Epilogue added 21d ago, after coverage quieted.
Momentum
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
Where it stands
Roche has announced successful Phase 3 study results for its KRAS G12C inhibitor, divarasib. The drug candidate was tested in a head-to-head study for non-small cell lung cancer (NSCLC), where it outperformed existing therapies.
Coverage from the Wall Street Journal, STAT, and BioPharma Dive emphasizes that the drug beat rivals from Amgen and BMS. Endpoints News and Fierce Biotech describe the result as a win over these competitors, with STAT reporting that the drug sets a new standard for KRAS-driven lung cancer.
Future developments center on the impact of these late-stage trial results on the treatment landscape for KRAS-driven lung cancer.
Synthesized by Archynetys from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 25d ago.
Who reported it (6)
- Roche KRAS drug succeeds in head-to-head lung cancer study BioPharma Dive · 26d ago
- Roche’s KRAS G12C inhibitor beats rivals in head-to-head Phase 3 study Endpoints News · 26d ago
- Roche orchestrates phase 3 KRAS lung cancer win over Amgen, BMS Fierce Biotech · 26d ago
- Roche drug sets new standard for KRAS-driven lung cancer STAT · 26d ago
- Roche's divarasib bests KRAS G12C rivals in late-stage NSCLC study FirstWord PHARMA · 26d ago
- Roche Lung-Cancer Drug Candidate Beats Existing Therapies in Late-Stage Trial WSJ · 26d ago
Answered
What is the name of the drug candidate?
The drug is identified as divarasib.
Which companies were the rivals in the study?
The coverage specifies Amgen and BMS as the rivals.
What specific condition was treated in the trial?
The study focused on KRAS-driven non-small cell lung cancer (NSCLC).
Topics
Related trends
New Alzheimer’s drug could stop disease
A new generation of Alzheimer’s drug treatments has entered the spotlight, promising potential to halt the disease before symptoms manifest.
A breakthrough in pancreatic cancer has experts excited
A new treatment for metastatic pancreatic cancer and KRAS-mutated cancers is generating optimism among experts and patients.
Revolution Medicines shares promising data around KRAS drug combination
Revolution Medicines has released promising Phase 1/2 clinical data for a KRAS drug combination targeting metastatic pancreatic cancer.
European Regulator Calls for Amgen’s Tavneos to Have Authorization Revoked
European regulators are recommending the revocation of marketing authorization for Amgen's autoimmune disease drug, Tavneos.